Semaglutide (LY-2189265) — Selective GLP-1 Receptor Agonist Peptide
Drive obesity and type-2 diabetes research with Semaglutide, the once-weekly analog that mimics endogenous GLP-1. In STEP Phase 3 trials, subjects experienced ≈ 15 – 17 % mean body-weight reduction over 68 weeks when combined with lifestyle intervention, establishing Semaglutide as a benchmark for incretin-based therapies.
-
Purity: > 99 % (HPLC)
-
Molecular Weight: ≈ 4.1 kDa (4 114 Da)
-
Form & Sizes: Lyophilized powder in 10 mg and 30 mg research-grade vials
-
Solubility: Sterile water or 0.6 % saline
-
Storage: –20 °C long-term; aliquoted reconstitutions ≤ –80 °C
For laboratory research use only. Not for human administration.